Volume : 10, Issue : 12, December – 2023
Title:
DOSING AND APPROPRIATE DURATION OF INTRAVENOUS ANTIBIOTIC FOR PEDIATRIC
Authors :
Yousef A. Alshomrani, Naif Suliman Almahyawi , AHMED OTHMAN ALMAILABI, Doa Omar Asraf , Khalid Khalaf Althebyani, Khalid Abdullah AlHarbi, Ghufran Omar Omran, Muntaha Hussain AlMalki , Raghad Ahmed AlSharif, Faihan Obaid Alzabni
Abstract :
The effective management of infections in pediatric patients necessitates the careful consideration of various factors, including the proper choice of antibiotics, optimal dosage, and duration of treatment. This approach aims to optimize the effectiveness of the medicines while minimizing any potential adverse effects. An essential aspect of achieving optimal dosing is a comprehensive comprehension of the pharmacokinetics and pharmacodynamics of the medications that are now accessible. The utilization of pharmacokinetic/pharmacodynamic (PK/PD) principles in dosing techniques can be advantageous in tailoring antibiotic dosages to ensure efficient eradication of bacteria in patients with modified pharmacokinetics or illnesses caused by organisms that are less sensitive or resistant. The objective of the present review is to examine the optimal duration and dose regimen for intravenous antibiotic therapy in the pediatric population.
A methodology for diluting antimicrobial agents in a healthcare facility has been developed specifically for the pediatric population. The purpose of this protocol is to ensure the proper administration of intravenous drugs in various healthcare settings, including inpatient units, emergency departments, and pediatric intensive care units (PICUs). The elements taken into account encompass the necessary diluent specifications and monitoring parameters, following a comprehensive evaluation of manufacturer labeling, primary literature, and drug information databases.
Cite This Article:
Please cite this article in press Yousef A. Alshomrani et al., Dosing And Appropriate Duration Of Intravenous Antibiotic For Pediatric, Indo Am. J. P. Sci, 2023; 10 (12).
Number of Downloads : 10
References:
1. Spencer S, Ipema H, Hartke P, et al. Intravenous push administration of antibiotics: literature and considerations. Hospital Pharm 2018;53(3):157–169.
2. Crane E, Lehr TV, Mathew M, et al. Developmental pharmacology and therapeutics. In: Buonocore G, Bracci R, Weindling M, ed. Neonatology. Milano: Springer; 2012.
3. Dyah kanya wati. Measuring and Managing Fluid Overload In Pediatric Intensive care unit: Current topics in intensive care medicine. 2018. 3–12. https://www.intechopen.com/books/current-topics-inintensive-care-medicine/measuring-and-managing-fluid-overloadin-pediatric-intensive-care-unit.
4. Mass B, Gilchrist A, Hellinger A, et al., ed. Pediatric guidelines for IV medication administration. Pharmacy and Therapeutic Committee. UMass Memorial Medical Centre https://www.umassmed.edu/ globalassets/anesthesiology/files/resources/2016-resources/ pediatric-guidelines-for-medications.pdf.
5. IV Administration Guidelines. Pharmacy Department Cork University Hospital. Updated May 2017 http://emed.ie/Pharmacology/Docs/ Pharm-CUH-IV-Guidelines-2017.pdf.
6. Lenz JR, Degnan DD, Hertig JB, et al. A review of best practices for intravenous push medication administration. J Infus Nurs 2017;40(6):354–358.
7. Grissinger M. Some IV medications are diluted unnecessarily in patient-care areas, creating undue risk. Pharm Therapeut 2017;42(8):490–492, 508.
8. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of ‘bug and drug’ Nat Rev Microbiol. 2004;2:289–300.
9. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26:1–10. quiz 11–2.
10. Bundtzen RW, Gerber AU, Cohn DL, Craig WA. Postantibiotic suppression of bacterial growth. Rev Infect Dis. 1981;3:28–37.
11. Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis Suppl. 1990;74:63–70.
12. Di Paolo A, Malacarne P, Guidotti E, Danesi R, Del Tacca M. Pharmacological issues of linezolid: an updated critical review. Clin Pharmacokinet. 2010;49:439–47.
13. Craig WA. Pharmacodynamics of antimicrobials: general concepts and applications. In: Nightingale CH, Ambrose PG, Drusano GL, Murakawa T, editors. Antimicrobial pharmacodynamics in theory and clinical practice. 2. New York, NY: CRC Press; 2007. pp. 1–19.
14. Eagle H, Fleischman R, Levy M. ‘Continuous’ vs‘discontinuous’ therapy with penicillin; the effect of the interval between injections on therapeutic efficacy. N Engl J Med. 1953;248:481–8.
15. Drusano GL. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis. 2003;36(Suppl 1):S42–50.
16. Jones EM, Howard WL. Streptomycin in the treatment of tuberculosis in children. Dis Chest. 1949;16:744–60.
17. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987;155:93–9.
18. Pagkalis S, Mantadakis E, Mavros MN, Ammari C, Falagas ME. Pharmacological considerations for the proper clinical use of aminoglycosides. Drugs. 2011;71:2277–94.
19. Touw DJ, Westerman EM, Sprij AJ. Therapeutic drug monitoring of aminoglycosides in neonates. Clin Pharmacokinet. 2009;48:71–88.
20. Zelenitsky SA, Harding GK, Sun S, Ubhi K, Ariano RE. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis. J Antimicrob Chemother. 2003;52:668–74.
21. Kashuba AD, Nafziger AN, Drusano GL, Bertino JS. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by Gram-negative bacteria. Antimicrob Agents Chemother. 1999;43:623–9.
22. Mohamed AF, Nielsen EI, Cars O, Friberg LE. Pharmacokinetic–pharmacodynamic model for gentamicin and its adaptive resistance with predictions of dosing schedules in newborn infants. Antimicrob Agents Chemother. 2012;56:179–88.
23. Beaubien AR, Desjardins S, Ormsby E, Bayne A, Carrier K, Cauchy MJ, et al. Incidence of amikacin ototoxicity: a sigmoid function of total drug exposure independent of plasma levels. Am J Otolaryngol. 1989;10:234–43.
24. Zappitelli M, Moffett BS, Hyder A, Goldstein SL. Acute kidney injury in noncritically ill children treated with aminoglycoside antibiotics in a tertiary healthcare centre: a retrospective cohort study. Nephrol Dial Transplant. 2011;26:144–50.
25. Bartal C, Danon A, Schlaeffer F, Reisenberg K, Alkan M, Smoliakov R, et al. Pharmacokinetic dosing of aminoglycosides: a controlled trial. Am J Med. 2003;114:194–8.
26. van Lent-Evers NA, Mathot RA, Geus WP, van Hout BA, Vinks AA. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther Drug Monit. 1999;21:63–73.
27. Ampofo K, Byington CL. Streptococcus pneumoniae. In: Long SS, Pickering LK, Prober CG, editors. Principles and practice of pediatric infectious disease. 4. Churchill Livingstone; 2012. pp. 721–8.
28. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J. 1996;15:255–9.
29. Canafax DM, Yuan Z, Chonmaitree T, Deka K, Russlie HQ, Giebink GS. Amoxicillin middle ear fluid penetration and pharmacokinetics in children with acute otitis media. Pediatr Infect Dis J. 1998;17:149–56.
30. Seikel K, Shelton S, McCracken GH., Jr Middle ear fluid concentrations of amoxicillin after large dosages in children with acute otitis media. Pediatr Infect Dis J. 1998;17:969–70.
31. Gudnason T, Gudbrandsson F, Barsanti F, Kristinsson KG. Penetration of ceftriaxone into the middle ear fluid of children. Pediatr Infect Dis J. 1998;17:258–60.
32. Kasiakou SK, Lawrence KR, Choulis N, Falagas ME. Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: a systematic review of pharmacokinetic and pharmacodynamic parameters. Drugs. 2005;65:2499–511.
33. Courter JD, Kuti JL, Girotto JE, Nicolau DP. Optimizing bactericidal exposure for β-lactams using prolonged and continuous infusions in the pediatric population. Pediatr Blood Cancer. 2009;53:379–85.
34. Bauer KA, West JE, O’Brien JM, Goff DA. Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections. Antimicrob Agents Chemother. 2013;57:2907–12.
35. Walker MC, Lam WM, Manasco KB. Continuous and extended infusions of β-lactam antibiotics in the pediatric population. Ann Pharmacother. 2012;46:1537–46.
36. Lowdin E, Odenholt I, Cars O. In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother. 1998;42:2739–44.
37. Hermsen ED, Ross GH, Rotschafer JC. Glycopeptide pharmacodynamics. In: Nightingale CH, Ambrose PG, Drusano GL, Murakawa T, editors. Antimicrobial Pharmacodynamics in theory and clinical practice. 2. New York, NY: CRC Press; 2007. pp. 189–215. [Google Scholar]
38. 50. Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis. 2011;52:975–81. [PubMed] [Google Scholar]
39. 51. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004;43:925–42.
40. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52:285–92.
41. Rybak M, Lomaestro B, Rotschafer JC, Moellering R, Jr, Craig W, Billeter M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66:82–98.
42. Frymoyer A, Hersh AL, Benet LZ, Guglielmo BJ. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J. 2009;28:398–402.
43. Frymoyer A, Hersh AL, Coralic Z, Benet LZ, Joseph Guglielmo B. Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: a Monte Carlo simulation. Clin Ther. 2010;32:534–42.
44. Chhim RF, Arnold SR, Lee KR. Vancomycin dosing practices, trough concentrations, and predicted area under the curve in children with suspected invasive staphylococcal infections. J Pediatr Infect Dis Soc. 2013;2:259–62.
45. Frymoyer A, Guglielmo BJ, Hersh AL. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant staphylococcal infections. Pediatr Infect Dis J. 2013;32:1077–9.
46. Le J, Bradley JS, Murray W, Romanowski GL, Tran TT, Nguyen N, et al. Improved vancomycin dosing in children using area under the curve exposure. Pediatr Infect Dis J. 2013;32:e155–63.
47. Hahn A, Vinks AA. Lower vancomycin serum concentrations might not be the answer. Pediatr Infect Dis J. 2013;32:1403–4.